Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

IDRA 3.65 -0.01 (-0.27%)
price chart
Idera Pharmaceuticals, Inc. Product Pipeline Review 2015 by Market Research ...
'Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Idera Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...
Stock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Announces ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, announced that it has appointed Mark J. Caseyas Senior Vice President, ...
Company Shares of Idera Pharmaceuticals, Inc. Drops by -4.3%  Insider Trading Report
Biotech Stocks - Is It Still Worthwhile Trading? Idera Pharmaceuticals Inc ...  Wall Street Observer
Hot Biotech Stocks To Watch Right Now - Idera Pharmaceuticals Inc (NASDAQ ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA) fell -1.35% to close last trading session at $3.66. The company, on June 29, 2015, announced that it has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors.
Analyst Price Target Update on Idera Pharmaceuticals, Inc.  OTC Outlook
Idera Pharmaceuticals Inc (NASDAQ:IDRA) Appoints New Secretary To The Board  FinancialsTrend
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Analyst Rating Update
Research firm Zacks has rated Idera Pharmaceuticals (NASDAQ:IDRA) and has ranked it at 3, indicating that for the short term the shares are a hold.
Biotech Top Gainers- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Celldex ...  StreetWise Report
Fall in love with these 3 Biotech stocks - Arena Pharmaceuticals, Inc ...  Wall Street Observer
Investor Insights on Idera Pharmaceuticals Inc (NASDAQ:IDRA)
[Globe Newswire] Idera Pharmaceuticals Inc (NASDAQ:IDRA)(TREND ANALYSIS) a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company ...
Idera Pharmaceuticals, Inc. Analyst Rating Update  Insider Trading Report
Idera Pharmaceuticals Receives Outperform Rating from Cowen and Company ...  Dakota Financial News
Idera Pharmaceuticals: Is The Writing On The Wall?
Idera Pharmaceuticals has shown recent successes in advancing their technology for treatment of many life threatening diseases, which makes it an attractive investment.
JP Morgan Initiates Coverage on Idera Pharmaceuticals Inc; Sees 60% Upside ...
J.P. Morgan analyst Anupam Rama initiated coverage on Idera Pharmaceuticals Inc (NASDAQ:IDRA) after finding potential value in the company's lead product, IMO-8400, in Waldenstrom's macroglobulinemia and diffuse large B-cell lymphoma.
Analyst Upgrades:, Inc., bluebird bio, Inc., and Idera ...  Schaeffers Research (blog)
Stock Upgrades & Downgrades: Idera Pharmaceuticals (NASDAQ:IDRA ...  Benchmark Monitor
Idera Pharmaceuticals, Inc. Shares Soar On Earnings
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Idera Pharmaceuticals (IDRA) Stock Gains After Earnings  CNA Finance (press release)
Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Reports First Quarter ...  Smarter Analyst
Pre-Market News Report on: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Yelp ...
On June 8, Idera Pharmaceuticals, declared that the company has reached a planned clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with ...
Idera Pharmaceuticals's "Outperform" Rating Reiterated at ...  Dakota Financial News
Idera Pharmaceuticals, Inc. Price Target Update  OTC Outlook
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Price Target Update
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares are expected to touch $6.5 in the short term. This short term price target has been shared by 2 analysts.